Skip to main content

Table 1 Baseline clinical characteristics and quality of life in PLWHIV diagnosed with HAND who participated in a randomised clinical controlled trial to test the effects of aerobic activity on QoL

From: Effects of aerobic exercise on quality of life of people with HIV-associated neurocognitive disorder on antiretroviral therapy: a randomised controlled trial

Approach

Intention-to-treat

Per protocol

Variables

Group

Statistics

Group

 

Exp (n = 38)

Control (n = 35)

Exp (n = 32)

Control (n = 35)

MR

MR

MWU-value

p

xÌ…(SD)/MR

x̅ ± (SD)/MR

t/MU-value

p

Depression (BDI)

141.23

138.69

367.00

0.946

36.20

36.81

636.500

0.900

ART adherence

178.90

165.14

520.88

0.001*

34.98

32.02

495.50

0.171

SPO2

172.64

194.24

563.75

0.044*

34.45

38.67

571.500

0.377

Heart rate

164.74

202.83

505.96

0.001*

73.70 (10.65)

77.57 (9.68)

− 1.610

0.112

Systolic BP

177.14

184.25

596.63

0.515

36.20

36.81

636.500

0.901

Diastolic BP

215.47

145.65

389.15

< 0.001*

38.97

27.32

351.000

0.013*

Physical QoL

163.77

194.84

505.89

0.004*

44.97 (14.94)

49.37 (16.18)

− 1.191

0.238

Psychological QoL

175.91

190.70

587.60

0.686

53.75 (17.37)

56.11 (14.52)

− 0.621

0.536

Social relationship QoL

161.97

191.20

496.73

0.006*

32.71

38.29

515.000

0.247

Environmental QoL

174.99

188.46

582.50

0.217

49.63 (15.71)

50.69 (13.60)

− 0.301

0.764

Overall QOL

165.11

201.29

509.62

0.001*

45.76 (12.32)

49.66 (7.65)

− 1.603

0.113

  1. Data for the exercise (Exp) and control groups are shown
  2. MR: Mean rank; MWU: Mann–Whitney test; x̅ (SD): mean (standard deviation); t: t-value
  3. *: significant at alpha = 0.05